Literature DB >> 17453294

Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy.

Jason S Gold1, David P Jaques, Klaus J Busam, Mary S Brady, Daniel G Coit.   

Abstract

BACKGROUND: It is common to obtain radiological studies around the time of a positive sentinel lymph node biopsy (SLNB) to exclude patients with distant metastases from completion lymph node dissection. The yield of such a work-up is unknown.
METHODS: Patients were identified from a prospectively maintained database. Medical records were reviewed.
RESULTS: Over an 8-year period, 181 patients had a positive SLNB. At least one study (computed tomography or magnetic resonance imaging of the brain; chest x-ray; computed tomography of the thorax, abdomen, or pelvis; positron-emission tomography scan; or bone scan) was obtained around the time of SLNB in 178 patients (98%). Studies were obtained after SLNB in 107 patients (59%). Studies ordered after SLNB resulted in indeterminate findings in 51 patients (48% of those studied). Among patients tested after SLNB, four were found to have metastatic disease (positive rate 3.7%). All of these patients had both a thick melanoma and macrometastasis within the SLN. The number of patients with indeterminate findings would be decreased and the yield of the work-up increased by 4 fold, by restricting the work-up to those with thick melanoma and macrometastasis.
CONCLUSIONS: Radiological studies obtained after a positive SLN produce indeterminate findings in about half of the patients and identify distant disease in 3.7%. Restricting work-up to patients with thick melanoma and macrometastasis on SLNB would spare patients from indeterminate findings and increase the yield of the evaluation.

Entities:  

Mesh:

Year:  2007        PMID: 17453294     DOI: 10.1245/s10434-007-9399-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines.

Authors:  Emanuela Romano; Michael Scordo; Stephen W Dusza; Daniel G Coit; Paul B Chapman
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

2.  The role of routine imaging in pediatric cutaneous melanoma.

Authors:  Hadeel Halalsheh; Sue C Kaste; Fariba Navid; Armita Bahrami; Barry L Shulkin; Bhaskar Rao; Michelle Kunkel; Nathan Artz; Alberto Pappo
Journal:  Pediatr Blood Cancer       Date:  2018-08-19       Impact factor: 3.167

3.  Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma.

Authors:  Erin R DeRose; Alexander Pleet; Wei Wang; Virginia J Seery; Mee Young Lee; Sharon Renzi; Ryan J Sullivan; Michael B Atkins
Journal:  Melanoma Res       Date:  2011-08       Impact factor: 3.599

4.  Treatment of cutaneous melanoma: current approaches and future prospects.

Authors:  Alain P Algazi; Christopher W Soon; Adil I Daud
Journal:  Cancer Manag Res       Date:  2010-08-17       Impact factor: 3.989

5.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Authors:  Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01

Review 6.  Staging of cutaneous melanoma.

Authors:  P Mohr; A M M Eggermont; A Hauschild; A Buzaid
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

Review 7.  Melanoma Radiological Surveillance: A Review of Current Evidence and Clinical Challenges.

Authors:  Matthew David Howard
Journal:  Yale J Biol Med       Date:  2020-03-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.